Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Talal Hilal, Vinay Prasad

Research output: Contribution to journalArticle


The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
Publication statusAccepted/In press - Jan 1 2018


ASJC Scopus subject areas

  • Oncology

Cite this